



23389

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.C. Don 1450 Alexandria, Vignia 22313-1450 www.aspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/792 237	03/03/2004	3736	1976	17517	14	17	14

CONFIRMATION NO. 4668

UPDATED FILING RECEIPT

OC000000013893635

COM INMATION NO. 4000

SCULLY SCOTT MURPHY & PRESSER, PC 400 GARDEN CITY PLAZA GARDEN CITY, NY 11530

MAR 2 5 2005

Date Mailed: 09/24/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Manabu Fujita, Tokyo, JAPAN; Akio Uchiyama, Yokohama-shi, JAPAN;

Assignment For Published Patent Application

OLYMPUS CORPORATION, TOKYO, JAPAN

Power of Attorney:

LEOPOLD PRESSER-19827 John Sensny-28757 Paul J. Esatto-30749 Frank S. DiGiglio-31346 Mark J. Cohen-32211 Edward W. Grolz-33705 Steven Fischman-34594 Peter Bernstein-43497

Domestic Priority data as claimed by applicant

Foreign Applications

JAPAN 2002-339719 11/22/2002

If Required, Foreign Filing License Granted: 05/24/2004

The number of your priority application, to be used for filing abroad under the Paris Convention is, US10/792,237

5167424366

Projected Publication Date: 01/06/2005

Non-Publication Request: No

Early Publication Request: No

Title

Capsulate medical system

Preliminary Class

600

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).





SCULLY, SCOTT, MURPHY & PRESSER 400 GARDEN CITY PLAZA

GARDEN CITY, NEW YORK 11530

Telephone: (516) 742-4343 Facsimile: (516) 742-4366 E-Mail: intprop@ssmp.com

FACSIMILE TRANSMISSION

To:

U. S. Patent and Trademark Office

Attention: Corrected Filing Receipt

Date:

March 18, 2005

Fax #

703-308-7751

Pages 5

From:

SCULLY, SCOTT, MURPHY & PRESSER

Re: Manabu Fujita, et al.

> U.S. Patent Appln. No. 10/729,237 CAPSULAR MEDICAL SYSTEM

Docket: 17517

COMMENTS:

The Updated Filing Receipt for the above-identified Patent Application has the Title incorrect and should read:

TITLE: CAPSULAR MEDICAL SYSTEM

Please send to us a corrected Filing Receipt with the information as it is shown on the pages to follow.

Thank you.

If there are any problems concerning this facsimile, please call (516) 742-4343 and ask for Talibah Washington, Ext. 533.

CONFIDENTIALITY: The documents accompanying this facsimile transmission may contain information which is either confidential or legally privileged and is intended only for the authorized use of the individual or entity named above without right of publication or republication, dissemination or disclosure except as expressly set forth or established by course of dealing. All rights are reserved. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of the contents of this facsimile is prohibited. If you received this transmission in error, please notify us immediately by telephone to arrange for return of the documents.



Approved for use through 10/31/102. OMB 0651-0032

Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Declaration and Power of Attorney for Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

	- G 84
私は、以下に記名された発明者として、ここに下記の通り宜言する: 私の住所、郵便の宛先十して国際は、私の氏名の後に記載された通りである。	My residence, past office address
下記の名称の発明について、特許請求抗國に記載され、且つ特許が求められている発明主題に関して、私は、最初、最先且つ唯一の発明者である(唯一の氏名が記載されている場合)が、或いは最初、最先日の共同発明者である(複数の氏名が記載されている場合)と信じている。	next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled
	CAPSULAR MEDICAL SYSTEM
上記是明の明日会はここに避付されているが、下記の額がチェック されている場合は、この題りでない: の日に出頭され、 この出頭の米田出頭番号主たはPCT国際出缸番号は、 であり、且つ の日に補正された出頭(該当する場合)	the specification of which is attached hereto unless the following box is checked: was filed on. as United States Application Number or PCT International Application Number and was amended on
私は、上記の存正書によって補正された、符許請求和盟を含む上記 相当を検討し、且つ内容を理解していることをここに表明する。	I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.
払は、達邦規則法典第37届規則1.56に定着をれている、特許 について重要な情報を買示する最超があることを認める。	I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations,

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the need of the individual case. Any comments on the amount of time you are required to complete this form should be sent to Chief Information Officer, U.S. Patent and Trademark Uffice.

Washington DC 2023 1. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission 15.

In consideration of One Dollar (\$1.00), and other good and valuable considerations, the receipt of which is hereby acknowledged, we , the undersigned,

Hereby sell, assign and transfer to Olympus Corporation

a corporation

of Japan having a place of business at 43-2, Hatagaya 2-chome, Shibuya-ku, Tokyo, Japan

its successors, assigns and legal representatives, the entire right, title and interest for all countries, in and to any and all improvements which are disclosed and claimed, and as possessed by the undersigned, any and all improvements which are disclosed but not claimed, in the application for United States Patent, which has been executed by the undersigned

on even date herewith

and is entitled

CAPSULAR MEDICAL SYSTEM

and in and to said application and all divisional, continuing, substitute, renewal, reissue, and all other applications for Letters Patent which have been or shall be filed on any of said improvements disclosed in said application; and in and to all original and reissued patents which have been or shall be issued on said improvements;

Authorize and request the Commissioner of Patents to issue to said Assignee, the corporation above named, its successors, assigns and legal representatives, in accordance with this assignment, any and all United States Letters Patent on said improvements, or any of them, disclosed in said application;

Agree that said Assignee may apply for and receive foreign Letters Patent for said improvements, or any of them; and may claim, in applications for said foreign Letters Patent, the priority of the aforesaid United States application under the provisions of the International Convention; and that, when requested, without charge to but at the expense of said Assignee, its successors, assigns and legal representatives, to carry out in good faith the intent and purpose